After FDA nod, Better Therapeutics races to boost dwindling cash

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday. The latest on GSK’s AI research, MyChart message billing, & new role for UCSF digital health lead

After FDA nod, Better Therapeutics races to boost dwindling cash

Better Therapeutics has cleared one hurdle: The Food and Drug Administration last week authorized the company to market AspyreRx, its prescription app which uses CBT to treat type 2 diabetes. Better now needs money, and fast. The public company recently raised $6.5 million in a stock sale to supplement its existing reserves, but it’s on the hunt for a medical device or pharmaceutical company partner that can provide the capital needed to fuel commercialization. CEO Frank Karbe told me the company hopes to have a deal in place by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In